Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference

Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3] - The company is currently developing and commercializing products for pulmonary hypertension and other applications using its proprietary PRINT Technology [3] - Liquidia's lead candidate is YUTREPIA™ (treprostinil) inhalation powder, aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [3] - The company is also working on L606, a sustained-release formulation of treprostinil, and markets generic Treprostinil Injection for PAH treatment [3] Upcoming Events - Liquidia will present an overview of its business at the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025, at 8:45 a.m. ET [1] - Access to a webcast of the presentation will be available on the "Investors" page of Liquidia's website, with an archived version accessible for at least 30 days post-event [2]